Compare ON Holding AG (ONON) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ON Holding AG vs Spyre Therapeutics Inc. Common Stock — how do they compare? ON Holding AG trades at $35.37 (market cap $11.86B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: ON Holding AG is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, ON Holding AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ON Holding AG for 24 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| ONON | SYRE | |
|---|---|---|
Market Cap | $11.86B | $7.52B |
Volume | 8,624,555 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.63 | $108.92 |
52-Week Low | $26.76 | $22.18 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $11.02B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONON trades at $35.49, up 0.4% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.44, and announced a $1 billion share buyback program through 2029 alongside ambitious long-term growth targets. Revenue for 2025 was $3.01 billion with a net income margin of 12.3% and robust cash flow from operations of $359.5 million.
The outlook is positive, driven by earnings momentum, strategic expansion, and shareholder returns, but risks include high valuation multiples and competitive pressures. Analyst consensus is strongly bullish with a $42.26 price target, suggesting potential upside from current levels.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
